Drug Profile

Gemfibrozil - Forest Hills Lab

Alternative Names: FHL-301

Latest Information Update: 17 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Forest Hills Lab
Class Antihyperlipidaemics; Antiparkinsonians; Ethers; Fibric acid derivatives; Pentanoic acids
Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Parkinson's disease

Most Recent Events

17 Jan 2024 Phase-II clinical trials in Parkinson's disease in USA (PO) prior to January 2024 (Forest Hills Lab pipeline, January 2024)
10 Jul 2023 Preclinical trials in Parkinson's disease in China (PO)
27 Jun 2023 Forest Hills Lab plans a phase II trial for Parkinson's disease (In adults, In the elderly) (PO) in November 2023 (NCT05931484)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com